Results

Bayer says its drug extends lives of liver cancer patients

Bayer AG said on Thursday its Regorafenib cancer treatment drug helped extend the lives of liver cancer sufferers according to the results of a Phase III clinical trial. Bayer now plans to file for regulatory approval of the oncology compound, which is also know as Stivarga, it said. The German company said it plans to submit the data from its study as the basis for marketing authorisation of Regorafenib in the treatment of inoperable liver cancer in 2016.

Brain scans could predict patients at risk of major depression

By Kate Kelland LONDON (Reuters) – Scientists studying people with depression say brain scans could be used to predict who is most likely to relapse, an approach that could help doctors make better decisions about who should stay on antidepressants and who should stop. In a small study of 64 patients, the researchers found that significant differences showed up in brain scans of those who later went on to have a recurrence of their depression. While the results need first to be replicated and improved upon, Roland Zahn, who led the work, said the approach may prove important in the future “as there are currently no accurate ways to predict those who will have a recurrence following recovery”.

Currently browsing tag